ANRO
What one share of Alto Neuroscience holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Through insights derived from our scalable and proprietary Precision Psychiatry Platform, or our Platform, we aim to discover brain-based biomarkers to better identify which patients are more likely to respond to our novel product candidates.
Alto Neuroscience’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.38 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$1.94 |
| Cash and investments | $6.95 |
| Debt | $0.46 |
| Book value | $6.25 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$9.73 | $0.13 | −$9.09 | — | −$18.70 |
| 2024 | — | −$2.50 | $0.08 | −$2.01 | — | $5.61 |
| 2025 | — | −$2.19 | $0.00 | −$1.80 | — | $4.73 |